NCT03894618 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03894618
Title	SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
Recruitment	Completed
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	Shattuck Labs, Inc.
Indications	lung squamous cell carcinoma lung adenocarcinoma gastric adenocarcinoma anal canal squamous cell carcinoma Advanced Solid Tumor adenosquamous lung carcinoma cervical squamous cell carcinoma renal cell carcinoma melanoma diffuse large B-cell lymphoma Hodgkin's lymphoma gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma transitional cell carcinoma skin squamous cell carcinoma
Therapies	SL-279252
Age Groups:	adult \| senior
Covered Countries	USA \| ESP \| CAN \| BEL

Facility	City	State	Zip	Country	Details
The Sarah Cannon Research Institute	Nashville	Tennessee	37203	United States	Details
The University of Texas MD Anderson Cancer Center	Houston	Texas	77030	United States	Details
Leuven Cancer Institute	Leuven		3000	Belgium	Details
Princess Margaret Cancer Center	Toronto	Ontario	M5G 1Z5	Canada	Details
Vall d'Hebron Institut D' Oncologia	Barcelona		08035	Spain	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT03894618Clinical Trial Detail